Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 20/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20363371 | 0.98 | OPRK1 (0.62) | OPRK1OPRM1 | |
| SCHEMBL17132155 | 0.94 | OPRK1 (0.73) | OPRK1OPRM1 | |
| SCHEMBL11931972 | 0.92 | OPRK1 (0.69) | OPRK1OPRM1 | |
| SCHEMBL20363363 | 0.92 | OPRK1 (0.65) | OPRK1OPRM1 | |
| SCHEMBL20363368 | 0.92 | OPRK1 (0.63) | OPRK1OPRM1 | |
| SCHEMBL19249464 | 0.90 | OPRK1 (0.62) | OPRK1OPRM1 | |
| SCHEMBL21233466 | 0.90 | OPRK1 (0.57) | OPRK1 | |
| SCHEMBL21286538 | 0.90 | OPRK1 (0.60) | OPRK1OPRM1 | |
| SCHEMBL21886313 | 0.88 | OPRK1 (0.66) | OPRK1OPRM1 | |
| SCHEMBL13290847 | 0.87 | OPRK1 (0.74) | OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11033629-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200085961-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | CARA THERAPEUTICS, INC. | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11033629-B2 | Oral formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | OPRK1 1/4885OPRM1 5/4885 |
| US-20200085961-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | OPRK1, OPRL1, OGFR | OPRK1 1/4885OPRM1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.